Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study in RAD 001 Patients With Relapse AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients from 18 to 65 years old~* AML in relapse more than 1 year after CR~* inform consent signed~Exclusion Criteria:~* age more than 65~* cardiac insufficiency~* renal insufficiency~* hepatic disease~* other type of AML~* blastic MCL~* HIV positive serology~* other malignancy~* pulmonary infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RAD 001 (Type: EXPERIMENTAL): RAD 001 in day 1 and day 7 from 10 mg to 50 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).